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In this paper, a second-derivative spectrophotometric method of assaying Sep-
talen
®
pellets (Krka, Novo Mesto, Slovenia), which contain lidocaine 1 mg, and
cetrimoniumbromide 2mg, is described. Lidocaine, 2-(diethylamino)-N-(2,6-dimethyl-
phenyl)-acetamide, is a local anesthetic with pronounced antiarhythmic and anticonvul-
sant properties. Cetrimonium bromide,N,N,N-trimethyl-l-hexadecanaminium bromide,
is a topical antiseptic and cleansing agent. Lidocaine was determined at 250 nm using
the "zero crossing" technique because the signals of centrimonium bromide and the
colour ingredient are zero at this wavelength. Cetrimonium bromide was determined by
correction of the peak amplitude at 215 nm according to lidocaine. In choosing the
optimal magnitudes for the simultaneous determination of both drugs, the following
criteria were considered: (1) the linearity of the calibration graphs as given by the
correlation coefficients, (2) the intercept, (3) the sensitivity as given by the regression
coefficient, (4) the degree of interference in the derivative measurement by the presence
of the other compound, as given by the relative percent error and by the relative recovery,
and (5) the reproducibility, as given by the coefficient of variation, calculated by
recording the second-derivative spectra.
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Septalen® pellets are a combination of the local anesthetic and topical antiseptic
agents. The aim of these investigations was to develop a method for the simultaneous
determination of the pharmaceutically active ingredients in Septalen® pellets.
Lidocaine is official in the USP 231 and British Pharmacopoeia,2 but centri-
moniumbromide only in theBritishPharmacopoeia. Titration in non-aqueousmedia
with perchloric acid using the potentiometric determination of the end point is
prescribed for lidocaine in British Pharmacopoeia, but in USP 23 it is the liquid
chromatography. For cetrimonium bromide it is an iodometric titration.
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Lidocaine has been determined in simple pharmaceutical dosage forms or in
combinations with some other drugs. In the presence of cocaine35 or some other
pharmaceutical substances,6,7 lidocaine was determined spectrophotometrically or
by using the atomic absorption spectrophotometric method.8,9 HPLC techniques
have been used for the determination of lidocaine in human blood 10,11 or in some
pharmaceuticals.12 Of the electrochemical methods, ion-selective electrodes1315
are themost important. Cetrimoniumbromidewas analysed using fluorimetic16 and




A Beckman DU Series 600 spectrophotometer, with 1 cm quartz cells and the experimental
conditions: Dl = 2 nm and scan speed 2400 nm/min, was used. The second-derivative spectra 2D =
d2A/d l 2 were recorded in the range from 200 nm to 300 nm against 0.1 mol/L hydrochloride acid.
Materials and reagents
All materials and reagents used were of analytical grade. Hydrochloric acid (Zorka Pharma
d.d., [abac) was used as the solvent for the spectrophotometric assay. Septalen® pellets (lidocaine 1
mg, and cetrimonium bromide 2 mg) is the official formulation by Krka, Novo Mesto, Slovenia. The
USP standard substances of lidocaine and cetrimonium bromide, as well as the standards of colour
ingredients and Septalen® pellets were obtained from Krka, Novo Mesto.
Procedure
Stock solutions were prepared by dissolving the respective standard substance in 0.1 mol/L
hydrochloric acid to obtain a concentration of 0.25 mg/mL for lidocaine and 0.5 mg/mL for cetri-
moniumbromide. For the calibration curve, a series of eight solutionswas prepared in the concentration
range from 5.0 to 30.0 m g/mL for lidocaine and from 10.0 to 60.0 m g/mL for cetrimonium bromide.
To prove the validity and applicability of the proposed derivative spectrophotmetric method, a
laboratory mixture of standard substances of lidocaine and cetrimonium bromidewas made in the ratio
which corresponded to that in the Septalen® pellets. A stock solution of the laboratory mixture was
made by dissolving 10.0 mg lidocaine and 20.0 mg cetrimonium bromide with 0.1 mol/L hydrochloric
acid in a 100mLvolumetric flask. The concentration of this solution was 100 m g/mL for lidocaine and
200 m g/mL for cetrimonium bromide. The declared colours were added to the laboratory mixture in
the corresponding ratios. From this laboratorymixture solution, three series of ten solutions weremade
the concentrations of which were: 7.5 m g/mL, 10.0 m g/mL and 12.5 m g/mL of lidocaine and 15.0
m g/mL, 20.0 m g/mL and 25.0 m g/mL for cetrimonium bromide.Then, the second-derivative spectra
were measured. In the same way, preliminary decolouration of the three mentioned series of dilutions
of the laboratory mixture were made using activated carbon. The stock solution of the laboratory
mixture was shaked with activated carbon for five minutes and then filtered.
To analyse the Septalen® pellets, ten pellets were accurately weighed and finally powdered.
The powdered pelletswere transferred into a 100mLvolumetric flask, 80mLof 0.1mol/Lhydrochloric
acid was added and the powder dissolved in an ultrasonic bath for 30 min. The volumetric flask was
filled to themarkwith 0.1mol/Lhydrochloric acid and the resulting solution filtered. The concentration
of this solution was 100 m g/mL of lidocaine and 200 m g/mL of cetrimonium bromide. The diluted
solutions was prepared by the same procedure as was used for the laboratory mixture.
The second-derivative spectra of the laboratory mixture and of the Septalen® pellets were
recorded in the range from 200 nm to 300 nm against the 0.1 mol/L hydrochloric acid.
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RESULTS ANDDISCUSSION
The classical spectrophotometric methods are not suitable for analysing a
multicomponent mixture because the absorption spectra of the components overlap.
This is often further complicated by interference from the formulationmatrix. Also,
the energy changes in the molecules are very inhomogeneous, causing wide and
complex absorption bands, which are not characteristic enough for the identification
or quantification of the substances in a multicomponent mixture. Derivative spec-
troscopy is a simple technique for magnifying the fine structure of spectral curves.
It consists of calculating the first, second, or higher order derivative of a spectrum
with respect to wavelength or frequency and plotting this derivative rather that the
spectrum itself. Higher order derivative spectrophotometry enables the problems of
overlapping bands in the spectra to be solved. The resolution increases with the
derivative order. It is most important to choose the optimal derivative order to
resolve the absorption spectra. For a quantitative analysis it is necessary to measure
the peak amplitude of the derivative spectra in the concentration range of the
Lambert-Beer linearity.
The zero order, first, second, third and fourth-derivative spectra for all the
investigated components of Septalen® pellets were recorded in the wavelength
range from 200 nm to 300 nm. For the simultaneous determination the second-de-
rivative order 2D was chosen (Fig. 1).
Lidocaine was determined at 250 nm, while cetrimonium bromide was deter-
mined at 215 nm. The signal at 250 nm corresponded to lidocaine, while the
absorption of cetrimonium bromide and the colour ingredients at this wavelength
are zero. For this reason the "zero crossing" technique for the determination of
lidocaine in combination with cetrimonium bromide at 250 nm was chosen. How-
ever, the determination of cetrimonium bromide necessited a correction of the peak
amplitude at 215 nm. It demanded the calculation of the participation factor
(correction factor) for lidocaine at the wavelength for cetrimonium bromide deter-
mination. The factor shows the participation of one component in the mixture with
Fig. 1. Second-derivative spectraof




caine b), cetrimonium bromide c),





the other when the bands overlap. It could be calculated from the calibration spectra
of lidocaine, because the ratios of the characteristic signals at the chosenwavelength
(in our case: for lidocaine at l = 215 nm) and the signals at the wavelength where






is the peak amplitude for lidocaine in the second-derivative spectra at
250 nm and D215
L
is the peak amplitude for lidocaine in the second-derivative
spectra at 215 nm.
Thismeans that the participation of lidocaine in themixture with cetrimonium
bromide at 215 nm is given by:
D215L  = 
D250L
f
The total peak amlitude (D215S) of the mixture of lidocaine and cetrimonium
bromide at 215 nm is:
D215S  = D215L  + D215C
whereD
C
215 is the peak amplitude for cetrimonium bromide at 215 nm. The signals
of the colour ingredients were zero at 215 nm.
Under the described experimental conditions, the calibration curves, obtained by
plotting 2D values versus concentration at the mentioned characteristic wavelengths,
show linear relationships in the following concentration ranges: 5.0 to 30.0 m g/mL for
lidocaineand10.0 to60.0 m g/mLforcetrimoniumbromide.Thecalibrationcurveswere
in agreement with the Beers law. The regression equations for the investigated
substances were calculated including the correlation coefficient (r)(Table I).
TABLE I. Calibration curve for Septalen
®
pellets
Parameters Lidocaine ( l =250 nm) Cetrimonium bromide ( l =215 nm)
Concentration range ( m g/mL) 5.030.0 10.0  60.0
y = ax + b y = 0.00002x + 0.0000039 y = 0.000094x + 0.00006
Correlation coefficient r = 0.9991 r = 0.9994
Limit of detection LD = 0.075 m g/mL LD = 0.083 m g/mL
n = 10
For the quantitive analysis of Septalen® pellets, three series of ten solutions
were prepared. Table II presents the results of the determination of lidocaine and
cetrimonium bromide in the Septalen® pellets under the described experimental
conditions. The validation parameters (linearity, selectivity, accuracy, precision)
were also determined. The derivative spectrophotometric method is selective be-
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cause the excipient did not interfere during the determination of the components of
the Septalen® pellets. The small values of the coefficient t
a
show good accuracy
and the coefficient of variation confirms the precision of the method.
TABLE II. Second-derivative spectrophotometric determination of Septalen
®
pellets
Taken/( m g/mL) Found/( m g/mL) Recovery/% CV/%
Lidocaine 7.5 7.40– 2* 99.2 2.8
10.0 10.2 – 0.2 102.0 2.4
A 12.5 12.5 – 0.3 100.0 2.0
Cetrimonium 15.0 15.0 – 0.3 100.0 2.2
bromid 20.0 20.2 – 0.3 100.9 1.5
25.0 25.0 – 0.5 100.2 2.2
Lidocaine 7.5 7.4– 0.2 99.2 2.8
10.0 10.0 – 0.2 100.0 2.4
B 12.5 12.4 – 0.2 99.7 2.3
Cetrimonium 15.0 14.9 – 0.3 99.8 1.4
bromid 20.0 19.8 – 0.5 99.2 2.6
25.0 24.8 – 0.3 99.2 1.5
* Sd (n = 10); A  Septalen
®





The second-derivative spectra of the investigated substances is suitable for
the simultneous determinationof the compositionofSeptalen® pellets. Theobtained
results are accurate and precise which is confirmed by the statistical parameters
(standard deviation, coefficient of variation and recovery values). There was no
interference of the excipient in the pellets. The second-derivative spectrophotomet-
ric method can be proposed for the simple, rapid, simultaneous, selective, accurate
and precise determination of the components of Septalen® pellets or a correspond-
ing multicomponent mixture. The obtained results confirms that the aim of the
investigations (to develop a method for the simultaneous determination of the
pharmaceutically active ingredients in Septalen® pellets with a good accuracy and
precision) was reached.
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U ovom radu opisana je derivativna spektrofotometrija izvoda drugog reda za
odre|ivawe Septalen® pastila (Krka, Novo Mesto, Slovenija), koje sadre lidokain 1
mg, i cetrimonijum-bromid 2 mg. Lidokain, 2-(dietilamino)-N-(2,6-dimetil-fenil)-
acetamid, je lokalni anestetik sa izrazitim antiaritmi~nim i antikonvulzivnim
osobinama. Cetrimonijum-bromid, N,N,N-trimetil-1-heksadekanaminijum-bromid je
povr{inski antiseptik i agens za ~i{}ewe. Lidokain je odre|ivan na talasnoj duini
od 250 nm kori{}ewemmetode "nultog preseka", jer su signali za cetrimonijum-bromid
i boju bili nula na toj talasnoj duini. Cetrimonijum-bromid je odre|ivan metodom
korekcije na 215 nm u odnosu nalidokain.Prikazani su rezultatiodre|ivawa aktivnih
komponenti Septalen® pastila u prisustvu boje ili sa prethodnim obezbojavawem. Pod
izabranim eksperimentalnim uslovima odre|eni su i slede}i kriterijumi za optimi-
zaciju predloene derivativne spektrofotometrijskemetode: (1) linearnost kalibra-
cione krive data je korelacionim koeficijentom, (2) presek sa ordinatom, (3) ose-
tqivost je data regresionim koeficijentom, (4) uticaj prisustva ostalih komponenti
na derivativna merewa dat je relativnom gre{kom i "recovery" vredno{}u i (5) repro-
duktivnost je data koeficijentom varijacije.
(Primqeno 27. oktobra 1999, revidirano 28. februara 2000)
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